Prothena Corp Public

PRTANasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$406.332 M

$7.92 -5.66%

Close of 6 Nov 2026

As of 6 Nov 2026, Prothena Corp Public (PRTA) has a market capitalization of $406.3M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$9.68M

#3139 by revenue

Earnings

-$244.1M

Loss-making

Shares outstanding

51,349,796

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#201Phathom PharmaceuticalsPHAT$413.0M
#202CorMedixCRMD$407.3M
#203Prothena Corp PublicPRTA$406.3M
#204Relmada TherapeuticsRLMD$402.7M
#205MapLight TherapeuticsMPLT$402.2M

Insiders buying

All insider buying →

4 open-market purchases by officers and directors of Prothena Corp Public, worth $2.83M. Grants and option exercises are excluded.

William P. Scully$1.22M
150,000 shares at $8.15 on 22 Oct 2026 · filed 26 Oct 2026
William P. Scully$843.5K
100,000 shares at $8.43 on 18 Sept 2026 · filed 21 Sept 2026
William P. Scully$439.4K
50,000 shares at $8.79 on 20 Aug 2026 · filed 21 Aug 2026
William P. Scully$323.2K
37,500 shares at $8.62 on 7 Aug 2026 · filed 10 Aug 2026

What if Prothena Corp Public were worth as much as…

Open the what-if tool →

Gold $28.2T

$550,029.96

Per share 69,492× higher

Bitcoin $1.53T

$29,761.16

Per share 3,760× higher

Apple $5.02T

$97,703.12

Per share 12,344× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Prothena Corp Public are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.